Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anticancer peptide therapeutics - Recepta biopharma

Next Previous
Search
Drug Profile

Research programme: anticancer peptide therapeutics - Recepta biopharma

Alternative Names: RB-10; RB-9; RebPep-100; RebPep-101

Latest Information Update: 21 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Recepta biopharma
  • Class Antineoplastics; Peptides
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malignant melanoma
  • No development reported Breast cancer; Glioblastoma; Ovarian cancer

Most Recent Events

  • 24 Aug 2023 Preclinical development in malignant melanoma is ongoing in Brazil (Recepta Bio pipeline, August 2023)
  • 28 Jun 2019 No recent reports of development identified for preclinical development in Malignant-melanoma in Brazil
  • 28 Jun 2019 No recent reports of development identified for research development in Breast-cancer in Brazil

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top